A Phase 1 interventional study of Baricitinib and Microgynon in Healthy Volunteers, sponsored by Eli Lilly and Company. Completed at 1 site in United Kingdom. Open to female participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-06-06.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to find out how the body absorbs and breaks down a common birth control pill called Microgynon when it is given with the study drug called baricitinib. Safety and the body's ability to tolerate baricitinib and Microgynon will also be studied. The study will last approximately 6 weeks for each participant.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Microgynon \[30 micrograms (µg) ethinyl estradiol and 150 µg levonorgestrel\] administered orally, once daily (QD), on Days 1 and 29. Baricitinib, 10 milligrams (mg), administered orally QD on Days 23 through 30.
Drug: Baricitinib · Drug: Microgynon
Administered orally
Also known as: LY3009104
Administered orally
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ethinyl Estradiol
Time frame: Days 1 and 29: predose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24 and 48 hours post dose
PK: Cmax of Levonorgestrel
Time frame: Days 1 and 29: predose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24 and 48 hours post dose
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity [AUC(0-∞)] of Ethinyl Estradiol
Time frame: Days 1 and 29: predose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24 and 48 hours post dose
PK: AUC(0-∞) of Levonorgestrel
Time frame: Days 1 and 29: predose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24 and 48 hours post dose
| Milestone | Baricitinib + Microgynon |
|---|---|
| Started | 20 |
| Received microgynon | 20 |
| Completed | 20 |
| Not completed | 0 |
| Milestone | Baricitinib + Microgynon |
|---|---|
| Started | 20 |
| Received at least 1 dose of baricitinib | 20 |
| Received microgynon | 18 |
| Completed | 18 |
| Not completed | 2 |
| Withdrew: Adverse event | 1 |
| Withdrew: Lost to follow-up | 1 |
| picograms/milliliter (pg/mL) | Microgynon Alone | Baricitinib + Microgynon |
|---|---|---|
| Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ethinyl Estradiol | 63.8 ± 23 | 59.7 ± 24 |
| pg/mL | Microgynon Alone | Baricitinib + Microgynon |
|---|---|---|
| PK: Cmax of Levonorgestrel | 3390 ± 34 | 3340 ± 26 |
| picograms*hour/milliliter (pg*hr/mL) | Microgynon Alone | Baricitinib + Microgynon |
|---|---|---|
| PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity [AUC(0-∞)] of Ethinyl Estradiol | 694 ± 24 | 697 ± 25 |
| pg*hr/mL | Microgynon Alone | Baricitinib + Microgynon |
|---|---|---|
| PK: AUC(0-∞) of Levonorgestrel | 48200 ± 58 | 42400 ± 45 |
Collected over Baseline through study completion (up to Day 40).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Microgynon Alone | — | 0/20 (0%) | 3/20 (15%) |
| Baricitinib | — | 0/20 (0%) | 4/20 (20%) |
| Baricitinib + Microgynon | — | 1/18 (5.6%) | 4/18 (22.2%) |
| Event | Microgynon Alone | Baricitinib | Baricitinib + Microgynon |
|---|---|---|---|
| Maternal exposure during pregnancyInjury, poisoning and procedural complications | 0/20 | 0/20 | 1/18 |
| Event | Microgynon Alone | Baricitinib | Baricitinib + Microgynon |
|---|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 1/20 | 2/20 | 0/18 |
| HeadacheNervous system disorders | 2/20 | 1/20 | 0/18 |
| DiarrhoeaGastrointestinal disorders | 0/20 | 0/20 | 1/18 |
| FlatulenceGastrointestinal disorders | 0/20 | 0/20 | 1/18 |
| Vulvovaginal candidiasisInfections and infestations | 0/20 | 0/20 | 1/18 |
| Decreased appetiteMetabolism and nutrition disorders | 0/20 | 1/20 | 1/18 |
All enrolled participants.
| Age, Continuous(years) | Baricitinib + Microgynon |
|---|---|
| Mean | 44.1 ± 12.7 |
| Sex: Female, Male(Participants) | Baricitinib + Microgynon |
|---|---|
| Female | 20 |
| Male | 0 |
| Ethnicity (NIH/OMB)(Participants) | Baricitinib + Microgynon |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 20 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Baricitinib + Microgynon |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 3 |
| White | 17 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Baricitinib + Microgynon |
|---|---|
| United Kingdom | 20 |
The record gives a start of Jul 2013, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2017, 3 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baricitinib